Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05DZK
|
||||
| Former ID |
DIB012061
|
||||
| Drug Name |
Interferon alpha 2a
|
||||
| Synonyms |
LBSI-5535; Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV); Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV), LG Life Sciences; Sr-IFN alpha (Biohydrix sustained release/weekly dosing, HCV), LGLS
|
||||
| Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Phase 3 | [525849] | ||
| Company |
LG Life Sciences Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Interferon alpha 2 ligand | Target Info | Modulator | [533362] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Regulation of autophagy | |||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Cytosolic DNA-sensing pathway | |||||
| Jak-STAT signaling pathway | |||||
| Natural killer cell mediated cytotoxicity | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Measles | |||||
| Influenza A | |||||
| Herpes simplex infection | |||||
| Autoimmune thyroid disease | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Downstream signaling in naï | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.